DiaMedica Therapeutics Inc.
DMAC
$6.05
$0.091.51%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 28.99% | 36.63% | 27.78% | 20.48% | -10.23% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.43% | 31.24% | 42.02% | 41.86% | 43.96% |
| Operating Income | -9.43% | -31.24% | -42.02% | -41.86% | -43.96% |
| Income Before Tax | -10.63% | -37.45% | -50.49% | -49.71% | -53.55% |
| Income Tax Expenses | 11.11% | -14.29% | -14.29% | -14.29% | -59.09% |
| Earnings from Continuing Operations | -10.63% | -37.39% | -50.40% | -49.62% | -53.07% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10.63% | -37.39% | -50.40% | -49.62% | -53.07% |
| EBIT | -9.43% | -31.24% | -42.02% | -41.86% | -43.96% |
| EBITDA | -9.44% | -31.17% | -42.22% | -41.86% | -43.97% |
| EPS Basic | 9.70% | -18.32% | -33.23% | -32.57% | -35.94% |
| Normalized Basic EPS | 9.64% | -18.45% | -33.37% | -32.59% | -36.33% |
| EPS Diluted | 9.70% | -18.32% | -33.23% | -32.57% | -35.94% |
| Normalized Diluted EPS | 9.64% | -18.45% | -33.37% | -32.59% | -36.33% |
| Average Basic Shares Outstanding | 22.45% | 16.09% | 12.84% | 12.87% | 12.61% |
| Average Diluted Shares Outstanding | 22.45% | 16.09% | 12.84% | 12.87% | 12.61% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |